• Home
  • Myeloma & Bone Cancer
    • Ask Dr. Berenson
    • Cure Updates
    • Patient Stories
    • I Have What?
  • Fundraising
    • Donate Now!
    • I Have What?
    • LA Marathon Fundraiser
    • How to Start a Fundraiser
    • Friend Raisers
    • Email Signup
  • About Us
    • About Dr. James Berenson
    • Directors
    • Research and Development Staff
    • Privacy Policy
    • Our Press Releases
  • Contact
  • Blog

Email Signup

Email Signup

Sign up for IMBCR’s Newsletter:

Web Form Generator

Search

Recent News

  • Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex)
  • Outcomes of Multiple Myeloma Patients Receiving Bortezomib, Lenalidomide and Carfilzomib
  • Improved Clinical Outcomes for Multiple Myeloma Patients Treated at a Single Specialty Clinic
  • Serum B-Cell Maturation Antigen: A Novel Biomarker to Predict Outcomes for Multiple Myeloma Patients
  • TRAF6 Is Over-Expressed in Multiple Myeloma and Blocking Its Intracellular Signaling Shows Both Anti-Tumor and Anti-Bone Resorptive Effects

News Archive

  • March 2017
  • June 2016
  • May 2016
  • March 2016
  • November 2015
  • May 2015
  • April 2015
  • August 2014
  • July 2014
  • May 2014
  • February 2014
  • September 2013
Copyright © 2017 Institute for Myeloma & Bone Cancer Research